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INTRODUCTION
The sense of taste is generally considered less important than vision andhearing. However, taste disorders can diminish the quality of life, lead to
work-related problems, and, in rare instances, may even become a life-
threatening hazard (Schiffman, 1983; Henkin, 1994; Ackerman and
Kasbekar, 1997; Heckmann et al., 2003). Dysgeusia is defined as a distorted
gustatory perception or persistent gustatory sensation in the absence of
gustatory stimulants (Deems et al., 1991; Brand, 2000). Frequently, patients
report a changed perception of gustatory stimuli. These stimuli are often
perceived as bitter, sour, or metallic. Treatment with zinc has been
attempted, but the results of clinical studies are equivocal (Schechter et al.,
1972; Henkin et al., 1976, 1999; Stoll and Oepen, 1994; Heyneman, 1996;
Seiden, 1997; Sakai et al., 2002). Among the reasons for these discrepancies
in the literature may be the small sample size, and the fact that the study
designs include different causes of dysgeusia. The purpose of this study was
to re-investigate the efficacy of zinc treatment in idiopathic dysgeusic
patients, in a randomized, placebo-controlled design. 
MATERIALS & METHODS
Patients
The dysgeusic patients who took part in this study were recruited from the
specialized interdisciplinary consultation unit for the care of patients with
orofacial diseases. The diagnosis of dysgeusia was based on the patients' reports
(Deems et al., 1991). From 1999 to 2001, 116 patients suffering mainly from a
dysgeusic taste disorder were seen; 50 patients suffering from idiopathic
dysgeusia were then enrolled in the study. The remaining 66 patients were
excluded. These patients either had symptomatic dysgeusia due to allergies to a
dental material, dysgeusia in combination with burning mouth syndrome
(Heckmann et al., 2001), systemic disease, neurological or psychiatric disease,
or metabolic disease, or the dysgeusia was, in all probability, caused by drugs
known to interfere with taste (Schiffman, 1983; Henkin, 1994; Ackerman and
Kasbekar, 1997). Approval was obtained from the ethics committee of the
University of Erlangen-Nuremberg (Nr. 2266), and the patients gave their
written informed consent.
Blinding and Randomization
Before patient recruitment, blinding and randomization were performed by an
independent individual using a special computer software program (RANDOM
by Joern Loetsch, Institute of Clinical Pharmacology, University of Frankfurt,
Germany). To this end, enrollment numbers were established, and the subjects to
be investigated were randomized by being grouped. Each group was made up of
four patients, i.e., two were assigned zinc, and two were assigned placebo.
Screw-top bottles were prepared containing either 100 zinc gluconate tablets
(140 mg, "Zink Verla"®) or 100 placebo tablets (lactose, "Placebo Lichtenstein 10
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mm"). The bottles were sealed and labeled with the study code and
the enrollment number. After the initial investigation for the
baseline data, each patient was given an enrollment number and the
corresponding screw-top bottle. The zinc and placebo showed no
significant difference in taste. Neither patient nor investigator had
any knowledge during the study as to whether the patient was being
treated with zinc or placebo. When the study was complete, this
information was then revealed by the independent individual.
Treatment
Zinc gluconate (140 mg/day, equivalent to 20 mg/day of elemental
zinc; cf. Henkin et al., 1999) and placebo were given to the
patients, with 26 subjects receiving zinc (five men, 21 women;
mean age, 61.1 yrs; age range, 41-82 yrs) and 24 subjects receiving
placebo (two men, 22 women; mean age, 61.0 yrs; age range, 47-
78 yrs). Patients were advised to swallow the drug whole on an
empty stomach with ample water. The therapy lasted for 3 mos.
Primary and Secondary Endpoints
The two primary endpoints were the scores of the taste test and
self-rated dysgeusia. Gustatory sensitivity was assessed by means
of the taste test. To this end, filter paper strips impregnated with 4
different concentrations of 4 taste qualities were placed on the left
and right sides of the anterior third of the patient's tongue, resulting
in a total number of 32 paper strips (Müller et al., 2003).
Before each administration of a taste strip, the patient's mouth
was rinsed with water. The taste strips were presented in increasing
concentrations. Taste qualities were applied in a randomized
fashion at each of the 4 levels of concentration. With the tongue
still extended, the subject was asked to identify the taste from a list
with the 4 descriptors—i.e., sweet, sour, salty, bitter—and the
respective 4 concentrations (sweet = 0.4, 0.2, 0.1, 0.05 g/mL
sucrose; sour = 0.3, 0.165, 0.09, 0.05 g/mL citric acid; salty = 0.25,
0.1, 0.04, 0.016 g/mL NaCl; bitter = 0.006, 0.0024, 0.0009, 0.0004
g/mL quinine-hydrochloride). The correlation coefficient for test
and re-test in healthy subjects was 0.68 (Müller et al., 2003).
The self-rated impairment due to dysgeusia was recorded by
means of a visual analogue scale (10-cm length is equivalent to
100%; no impairment = 0 units; extremely impaired = 10 units).
Secondary endpoints were the results of psychological tests
related to depression (Beck Depression Inventory, BDI; Beck et
al., 1961) and mood (von Zersen mood scale, ZMS; Heimann et
al., 1975). In addition, the levels of zinc, sodium, calcium,
potassium, and chloride in both the serum and saliva were
analyzed. All measurements were taken before and after therapy.
Based on our clinical experience (Müller et al., 2003), an
improvement by 6 points in the taste test can be regarded as
substantial, which typically also corresponds to the subjective
feeling of an improved sense of taste.
Statistical Analysis
The results were evaluated with the use of SPSS 11 for
WindowsTM. For the primary endpoints, an analysis of variance for
repeated measurements was performed with the two within-subject
factors 'session' (before, after therapy) and 'test' (taste test, self-
rated dysgeusia), and the between-subject factor 'treatment' (zinc,
placebo). Group comparisons were also performed with t tests for
independent samples. For reasons of normalization, differences
between the data obtained before and those obtained after therapy
were computed. In addition, correlations (Pearson) were calculated
between the variables of interest. The alpha level was set at 0.05.
RESULTS
All participants completed the study. The patients'
characteristics are listed in the Table.
The characteristics of the two groups before treatment did
not differ significantly. BDI and ZMS indicated a certain
degree of depression and mood impairment according to
published normative data (Beck et al., 1961). During the
observation period, none of the patients reported any treatment-
associated side-effects. With regard to the primary endpoints,
Table. Characteristics of Patients Before and After Treatment (means, standard deviations [SD]; zinc group, n = 26; placebo group, n = 24) and
Comparison of Data as Obtained before Treatment*
Zinc Treatment (n = 24) Placebo (n = 26) Comparison of Data
Before After Before After Before Treatment
Mean SD Mean SD Mean SD Mean SD t-value p-value
Age [yrs] 61.1 10.6 61.0 8.9 0.03 0.98
Duration of disease [mos] 39.8 41.3 47.6 68.6 0.54 0.59
Taste test 17.1 5.8 25.7 6.5 18.9 7.3 21.2 5.7 1.12 0.27
[no. correctly identified out of 32]
Self-rated impairment [%] 40.7 5.9 45.0 4.4 42.6 5.7 43.8 3.6 1.23 0.23
Scores of Beck 10.6 8.5 7.5 7.0 11.3 10.7 11.3 10.9 0.28 0.78
Depression Inventory (BDI)
Scores of Mood Scale (ZMS) 15.6 11.3 10.7 7.5 18.8 13.3 18.8 14.6 0.91 0.37
Zinc in serum [mg/dL] 72.78 18.38 81.53 19.61 67.90 14.64 72.01 10.22 1.01 0.32
Zinc in saliva [mg/dL] 5.95 3.65 9.04 13.04 4.51 3.53 6.22 4.46 1.42 0.16
Sodium in serum [mmol/L] 139.73 2.84 138.73 3.16 140.17 1.76 138.88 2.88 0.65 0.52
Sodium in saliva [mmol/L] 9.82 4.11 11.00 5.78 9.43 4.95 9.46 2.77 0.30 0.77
Potassium in serum [mmol/L] 4.14 0.58 4.32 0.42 4.40 0.46 4.65 1.25 1.76 0.09
Potassium in saliva [mmol/L] 29.44 41.11 21.22 4.69 20.00 6.59 20.40 6.10 1.11 0.27
Calcium in serum [mmol/L] 2.40 0.09 2.40 0.09 2.39 0.07 2.39 0.16 0.82 0.42
Calcium in saliva [mmol/L] 1.19 0.36 1.38 0.59 1.28 0.53 1.17 0.44 0.76 0.45
* There was no significant difference between the data before and the data after treatment.
 at LMU Muenchen on May 16, 2013 For personal use only. No other uses without permission.jdr.sagepub.comDownloaded from 
International and American Associations for Dental Research
J Dent Res 84(1) 2005 Zinc in Dysgeusia Treatment 37
an analysis of variance indicated a significant difference
between measurements obtained before and those obtained
after therapy (factor 'session': F = 52.6, p < 0.001). In addition,
the significant interaction between the factors 'session' and
'treatment' (F = 17.1, p < 0.001) indicated that treatment had
differential effects on patients treated with placebo or with
zinc. Specifically, the gustatory function of patients on zinc
improved in comparison with that of controls (t = 4.25, p <
0.001), and the patients rated the dysgeusia as being less severe
(t = 2.04, p = 0.048) (Fig.).
In terms of patient ratings of improvement in dysgeusia
(defined as an improvement of more than 5%), actual
improvement was seen in 13 of 26 patients receiving zinc
treatment (50%), while in the case of those receiving placebo
(25%), improvement was found in only six of the 24 patients.
In addition, zinc patients indicating improvement in dysgeusia
also exhibited an average improvement (by 10.7 points) in their
gustatory test scores, while the corresponding placebo patients
exhibited an average improvement of only 2.7 points. In
patients who had not indicated any improvement in dysgeusia,
average taste scores were found to increase by 6.4 points in
zinc patients and by 2.2 points in placebo patients.
When the secondary endpoints were reviewed, signs of
depression or lowered mood were found to have improved in
the zinc group (BDI score, t = 2.60, p = 0.012; ZMS, t = 2.13, p
= 0.039). No significant group differences were seen for the
other parameters investigated, with the exception of the
salivary calcium level, which was higher in zinc patients than
in controls (t = 2.18, p = 0.034). Interestingly, treatment with
zinc had no significant effect on levels of zinc measured in
serum (t = 0.83, p = 0.41) or saliva (t = 0.46, p = 0.65).
DISCUSSION
The results of this study indicate that zinc is useful in the
treatment of dysgeusia in terms of improvement of general
gustatory function. Dysgeusic sensations and general mood
scores also improved. Unexpectedly, these findings appeared to
be independent of the actual levels of zinc in serum or saliva.
Treatment with zinc in cases of dysgeusia is frequently
recommended (Heyneman, 1996), although the results of
published studies are equivocal. Reasons for these discrepancies
are, among other things, the small sample size, the open trial
design, inhomogeneous patient diagnosis involving patients
with smell disorder or symptomatic dysgeusia, and the inclusion
of zinc-deficient patients (Schechter et al., 1972; Henkin et al.,
1976, 1999; Stoll and Oepen, 1994; Sakai et al., 2002). To
prevent bias and to ensure that the groups of patients studied
were homogeneous, we enrolled only patients with idiopathic
dysgeusia and, hence, a normal serum zinc level.
In the study at hand, there was a striking gender imbalance,
with more females than males suffering from dysgeusia. This is
consistent with the clinical experience of our unit for the care
of patients with orofacial diseases (Heckmann et al., 2001). It
has been suggested that, among other things, hormonal changes
may be responsible for the initiation of this symptom
(Levenson, 2002).
No significant increase in serum zinc was found in the zinc
group. This may be due to the fact that zinc is a trace element
and is rapidly transferred into the cells. Zinc is of particular
significance, especially in cells with a high-rate turnover, such
as cells of the taste buds (Henkin, 1994; Umeta et al., 2000).
Thus, for the zinc dosage used, the insignificant change in
serum zinc can be explained.
No side-effects were reported in the present study. At
higher dosages, however, several side-effects can occur, such
as gastrointestinal or hematological disorders—e.g., anemia,
leukopenia, and neutropenia (Salzman et al., 2002)—and zinc
intoxication can occur in cases of extreme dosage (Chobanian,
1981).
The presence of elevated salivary calcium in the zinc-
treated patients is difficult to interpret. Our speculations center
on an increased calcium secretion due to the influence of zinc.
In previous studies, a salivary calcium-zinc exchange was
observed, whereby the absorption of zinc led to a release of
calcium (Ingram et al., 1992).
Several basic scientific studies indicate that zinc is an
extremely important factor in gustation. For example, zinc
appears to be of significance for the regeneration of taste bud
cells (Henkin et al., 1999). Zinc also seems to be crucial in the
regulation of metalloprotein expression and, in turn, for the
synthesis of growth hormones. Finally, zinc is assumed to
influence the activity of carbonic anhydrase VI, and thus, the
level of gustin, an important metalloprotein which has been
reported to act as a growth factor for taste bud cells (Henkin et
al., 1988). However, since the exact role that zinc plays in
gustation is not fully understood, further research is necessary
to explore the molecular and biological mechanisms underlying
the effects of zinc on taste (Seiden, 1997). Nevertheless, from
an empirical point of view, analysis of the current data suggests
that treatment with zinc is helpful in treating patients with
idiopathic dysgeusia.
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Figure. Taste test [number of taste strips (out of 32) correctly identified;
(A) and self-rated dysgeusia (in % of the visual analogue scale; (B)
before (black bars) and after (white bars) therapy (means, standard
errors of means; zinc group, n = 26; placebo group. n = 24).
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ERRATUM
In the manuscript, “Zinc Gluconate in the Treatment of Dysgeusia—a Randomized Clinical Trial” (J Dent Res 84:35-38), two of the
entries in the Table on page 36 are incorrect. The corrected text appears in bold below. The authors regret the error. 
Table. Characteristics of Patients Before and After Treatment (means, standard deviations [SD]; zinc group, n = 26; placebo group, n = 24) and
Comparison of Data as Obtained before Treatment*
Zinc Treatment (n = 24) Placebo (n = 26) Comparison of Data
Before After Before After Before Treatment
Mean SD Mean SD Mean SD Mean SD t-value p-value
Age [yrs] 61.1 10.6 61.0 8.9 0.03 0.98
Duration of disease [mos] 39.8 41.3 47.6 68.6 0.54 0.59
Taste test 17.1 5.8 25.7 6.5 18.9 7.3 21.2 5.7 1.12 0.27
[no. correctly identified out of 32]
Self-rated impairment [%] 40.7 5.9 45.0 4.4 42.6 5.7 43.8 3.6 1.23 0.23
Scores of Beck 10.6 8.5 7.5 7.0 11.3 10.7 11.3 10.9 0.28 0.78
Depression Inventory (BDI)
Scores of Mood Scale (ZMS) 15.6 11.3 10.7 7.5 18.8 13.3 18.8 14.6 0.91 0.37
Zinc in serum [microgram/dL] 72.78 18.38 81.53 19.61 67.90 14.64 72.01 10.22 1.01 0.32
Zinc in saliva [microgram/dL] 5.95 3.65 9.04 13.04 4.51 3.53 6.22 4.46 1.42 0.16
Sodium in serum [mmol/L] 139.73 2.84 138.73 3.16 140.17 1.76 138.88 2.88 0.65 0.52
Sodium in saliva [mmol/L] 9.82 4.11 11.00 5.78 9.43 4.95 9.46 2.77 0.30 0.77
Potassium in serum [mmol/L] 4.14 0.58 4.32 0.42 4.40 0.46 4.65 1.25 1.76 0.09
Potassium in saliva [mmol/L] 29.44 41.11 21.22 4.69 20.00 6.59 20.40 6.10 1.11 0.27
Calcium in serum [mmol/L] 2.40 0.09 2.40 0.09 2.39 0.07 2.39 0.16 0.82 0.42
Calcium in saliva [mmol/L] 1.19 0.36 1.38 0.59 1.28 0.53 1.17 0.44 0.76 0.45
* There was no significant difference between the data before and the data after treatment.
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